Quick Answer
Kymera Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $357.01 million for the year ending 2025.
- Kymera Therapeutics, Inc. showed an increase of +196.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $5.34 million | Q1 2020: $121.25 million | Q2 2020: $60.97 million | Q3 2020: $54.59 million | Q1 2021: $53.10 million | Q2 2021: $84.90 million | Q3 2021: $156.82 million | Q1 2022: $33.73 million | Q2 2022: $76.91 million | Q3 2022: $155.66 million | Q1 2023: $50.15 million | Q2 2023: $52.39 million | Q3 2023: $81.05 million | Q1 2024: $93.51 million | Q2 2024: $67.61 million | Q3 2024: $110.72 million | Q1 2025: $335.82 million | Q2 2025: $335.82 million | Q3 2025: $112.95 million.
- Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 369.7%.
- Historical annual values: Fiscal year 2025: $357.01 million | Fiscal year 2024: $120.26 million | Fiscal year 2023: $109.97 million | Fiscal year 2022: $68.40 million | Fiscal year 2021: $47.98 million | Fiscal year 2020: $31.00 million | Fiscal year 2019: $76.02 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: